Nurix Therapeutics officer proposes $90.1K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Nurix Therapeutics, Inc. officer Christine Ring filed a notice of a proposed sale of 5,394 common shares, with an aggregate market value of $90,079.80 and an approximate sale date of May 1, 2026. The shares listed for sale were acquired from the issuer as restricted stock units on April 30, 2026. The notice lists November 10, 2025 as the plan adoption or instruction date if relying on Rule 10b5-1.
Key Figures
Key Terms
Restricted Stock Units financial
Rule 10b5-1 regulatory
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What previous NRIX sales does Christine Ring report?
AI-generated analysis. How Rhea-AI works. Not financial advice.